NCT06643130View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

PHASE3RecruitingINTERVENTIONAL

Enrollment

162

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

HypertensionDyslipidemia

Interventions

DRUG

JW0104+C2402

For 8 weeks(PO (Per Oral), QD)

DRUG

JW0104+C2403

For 8 weeks(PO, QD)

DRUG

C2402

For 8 weeks(PO, QD)

Trial Locations (1)

05355

RECRUITING

Gangdong Sacred Heart Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY